

## **Triple therapy for exudative AMD**

Authors: Raimondo Forte, Paola Bonavolontà, Naples, Italy; Jean Paul Adenis, Pierre-Yves Robert, Limoges, France

### **Advantages:**

To reduce the number of retreatments with intravitreal anti- VEGF in exudative age related macular degeneration (AMD).

### **Methods:**

We evaluated all eyes with exudative AMD treated with bevacizumab or ranibizumab in monotherapy and in association with dexamethasone and photodynamic therapy with verteporfin (PDT).

### **Effectiveness / Safety:**

42 eyes were included in the triple therapy group, 31 eyes were included in the monotherapy group. Mean follow up was  $7.2\pm 5.1$  months in the triple therapy group and  $9.7\pm 4.2$  months in the monotherapy group ( $p=0.08$ ). The triple therapy group enjoyed a lower number of treatments per-month ( $0.29\pm 0.24$  vs  $0.37\pm 0.21$ ,  $p=0.001$ ) and a longer time before retreatment ( $6.1\pm 3.2$  vs  $4.3\pm 2.7$ ,  $p=0.001$ ). Both groups showed a similar improvement of both BCVA and foveal thickness (FT). No complications were reported.

### **Take home message:**

The combination of intravitreal anti-VEGF with dexamethasone and PDT seems effective in reducing the number of retreatments in exudative AMD.